Eli Lilly Reports P-III Study (LIBRETTO-531) Results of Retevmo (selpercatinib) for RET-Mutant Medullary Thyroid Cancer
Shots:
- The company highlighted the P-III study (LIBRETTO-531) results evaluating the safety and efficacy of Retevmo (highly selective and potent RET kinase inhibitor) vs cabozantinib or vandetanib (multikinase inhibitors) in a ratio (2:1) in 291 patients with progressive, advanced kinase inhibitor naïve RET-mutant MTC
- The study met its 1EPs & showed a significant and clinical improvement in PFS, AEs were generally consistent with those identified across the previously reported Retevmo development program (LIBRETTO-001/121/321)
- The results will be presented at an upcoming medical meeting, submitted to a peer-reviewed journal, and discussed with health authorities
Ref: PR Newswire | Image: Eli lilly
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
